Imperiale A, Olianti C, Mannelli M, La Cava G, Pupi A
Nuclear Medicine Unit, Department of Clinical Pathophysiology, University of Florence, Florence, Italy.
Q J Nucl Med Mol Imaging. 2005 Sep;49(3):287-96.
The aim of this study was three-fold: 1) to quantify [131I]-6beta-iodomethyl-norcholesterol ([131I]-NP-59) adrenal uptake trend in patients with incidentalomas, 2) to identify a specific uptake trend (TREND) capable of characterising pre-clinical Cushing syndrome (PC-CS) patients, 3) to assess the clinical availability of TREND as a prognostic factor of late clinical outcome in a cohort of patients with bilateral adrenal adenomas.
Fifty-seven consecutive patients were examined using three-head SPECT at 24, 48, 72 hours following intravenous injection of [131I ]-NP-59. On the basis of the absence or presence of hormonal abnormalities, the selected population was classified as GR1 or GR2, respectively. Adrenal glands were classified into 4 groups taking into account both the patient group (GR1, GR2) and the presence (+) or absence (-) of the adenoma (AD) on CT scan. Using ROI technique, adrenal-liver uptake ratio (A/L) was estimated bilaterally at 24, 48 and 72 hours. For each adrenal group, mean [131I]-NP-59 uptake trends were derived.
TREND was significantly different between GR1/AD+ and GR2/AD+. Among GR2/AD+ patients, TREND correctly identified PC-CS with a global accuracy of 74%. Two patients with bilateral incidentaloma developed an overt CS. In both patients, TREND correctly identified the hyperfunctioning adrenal, thus permitting an effective sparing adrenalectomy.
TREND seems to be a parameter which closely reflects adrenal physiological behaviour, especially in the case of bilateral adrenal involving. The possibility to quantify even contralateral adrenal uptake as standardised index provides additional useful information about normal adrenal parenchyma and, indirectly, about adenoma functional autonomy.
本研究的目的有三个方面:1)量化偶发瘤患者中[131I]-6β-碘甲基去甲胆固醇([131I]-NP-59)的肾上腺摄取趋势;2)确定一种能够表征临床前库欣综合征(PC-CS)患者的特定摄取趋势(TREND);3)评估TREND作为双侧肾上腺腺瘤患者晚期临床结局预后因素的临床实用性。
57例连续患者在静脉注射[131I]-NP-59后的24、48、72小时使用三头SPECT进行检查。根据是否存在激素异常,将选定的人群分别分类为GR1或GR2。考虑患者组(GR1、GR2)以及CT扫描上腺瘤(AD)的存在(+)或不存在(-),将肾上腺分为4组。使用ROI技术,在24、48和72小时双侧估计肾上腺-肝脏摄取率(A/L)。对于每个肾上腺组,得出平均[131I]-NP-59摄取趋势。
GR1/AD+和GR2/AD+之间的TREND有显著差异。在GR2/AD+患者中,TREND正确识别PC-CS的总体准确率为74%。两名双侧偶发瘤患者出现明显的库欣综合征。在这两名患者中,TREND正确识别了功能亢进的肾上腺,从而实现了有效的保留肾上腺切除术。
TREND似乎是一个密切反映肾上腺生理行为的参数,特别是在双侧肾上腺受累的情况下。将对侧肾上腺摄取量化为标准化指标的可能性提供了关于正常肾上腺实质的额外有用信息,并且间接地提供了关于腺瘤功能自主性的信息。